Cargando…

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis

Objective: This review was performed to compare the efficacy and safety among hospitalized patients with COVID-19 who received baricitinib and those who received tocilizumab independently with placebo or the standard of care (SOC). Methods: Relevant databases were searched for randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cherian, Jerin Jose, Eerike, Madhavi, Bagepally, Bhavani Shankara, Das, Saibal, Panda, Samiran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624173/ https://www.ncbi.nlm.nih.gov/pubmed/36330085 http://dx.doi.org/10.3389/fphar.2022.1004308

Ejemplares similares

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies
por: Kumar, S. Sajith, et al.
Publicado: (2022)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Is COVID-19 severity associated with telomere length? A systematic review and meta-analysis
por: Haridoss, Madhumitha, et al.
Publicado: (2023)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Association between blood lead levels and markers of calcium homeostasis: a systematic review and meta-analysis
por: Upadhyay, Kuldip, et al.
Publicado: (2022)

Editorial: Medication Safety in COVID-19 Management
por: Das, Saibal
Publicado: (2022)

Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost–utility studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Editorial: Medication safety in COVID-19 management, Volume II
por: Das, Saibal
Publicado: (2023)

Meta-analysis of economic evaluation studies: data harmonisation and methodological issues
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Assessment of Bone Turnover Biomarkers in Lead-Battery Workers with Long-Term Exposure to Lead
por: Ravibabu, Kalahasthi, et al.
Publicado: (2020)

Association of Musculoskeletal Disorders and Inflammation Markers in Workers Exposed to Lead (Pb) from Pb-battery Manufacturing plant
por: Ravibabu, Kalahasthi, et al.
Publicado: (2019)

Association between Musculoskeletal Pain and Bone Turnover Markers in Long-Term Pb-Exposed Workers
por: Kalahasthi, Ravibabu, et al.
Publicado: (2021)

Is State-Wise Healthcare Budget Allocation Consistent With the Disease Burden in India? A Quinquennial Account (2015–2019)
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Air pollution attributed disease burden and economic growth in India: Estimating trends and inequality between states
por: S, Sajith Kumar, et al.
Publicado: (2022)

A perspective on trends in air pollution attributed disease burden in India-Authors' reply
por: Sajith Kumar, S, et al.
Publicado: (2022)

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences
por: Noparatayaporn, Prapaporn, et al.
Publicado: (2021)

Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells
por: Liu, Shuang, et al.
Publicado: (2020)

Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
por: Sasidharan, Akhil, et al.
Publicado: (2022)

Tocilizumab and COVID-19: Timing of Administration and Efficacy
por: Abidi, Emna, et al.
Publicado: (2022)

Systematic review and meta-analysis of gallstone disease treatment outcomes in early cholecystectomy versus conservative management/delayed cholecystectomy
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
por: Kojima, Yuichi, et al.
Publicado: (2022)

Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
por: Shamail, Ghazala M. H., et al.
Publicado: (2021)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19
por: Belladonna, Maria Laura, et al.
Publicado: (2020)

Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: Cost effectiveness analysis from Indian context
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2023)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Economic evaluation of hepatitis A vaccines by income level of the country: A systematic review
por: Gurav, Yogesh Kirshnarao, et al.
Publicado: (2022)

Baricitinib treatment for refractory skin changes in POEMS syndrome: a case report
por: Xie, Jingjing, et al.
Publicado: (2023)

Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
por: Sun, Jing, et al.
Publicado: (2023)

Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis
por: Jahan, Nuzrath, et al.
Publicado: (2022)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
por: Smith, Daniel P., et al.
Publicado: (2021)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
por: Faria, Sofia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ukn898ucfcu2kpkm1klcnj85b6